Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Heparin induced thrombocytopenia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Heparin induced thrombocytopenia. Displaying page 1 of 1.
    EudraCT Number: 2007-000564-25 Sponsor Protocol Number: FLHIT Start Date*: 2007-04-04
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: Fondaparinux vs Lepirudin in the treatment of heparin-induced thrombocytopenia, with or without thrombosis. A multicenter, randomized, parallel group study of treatment with fondaparinux (7.5 mg s...
    Medical condition: thrombocytopenia heparin-induced
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062506 Heparin-induced thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-003122-28 Sponsor Protocol Number: ArgLepi-2006 Start Date*: 2008-12-19
    Sponsor Name:Heinrich-Heine-Universität Düsseldorf
    Full Title: Argatroban versus Lepirudin in Critically Ill Patients
    Medical condition: Critically ill patients are usually treated with heparin for anticoagulation. A serious complication of heparin therapy is heparin-induced thrombocytopenia type II (HIT). Patients with HIT have t...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10062506 Heparin-induced thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000730-42 Sponsor Protocol Number: ARG-E07 Start Date*: 2009-01-09
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation
    Full Title: An open-label, multi-centre, clinical study to collect information on the clinical use of argatroban in patients with heparin induced thrombocytopenia (HIT) Type II who require parenteral antithrom...
    Medical condition: Heparin induced thrombocytopenia (HIT) Type II
    Disease: Version SOC Term Classification Code Term Level
    9.1 10048672 Heparin-induced thrombocytopenia type II LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-002473-21 Sponsor Protocol Number: ERGCR-18-ORGHIT-001 Start Date*: 2019-03-05
    Sponsor Name:Aspen Global Incorporated
    Full Title: An Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Treatment of Subjects with Acute HIT (HITSOVA study)
    Medical condition: Acute Heparin-induced Thrombocytopenia (HIT)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10062506 Heparin-induced thrombocytopenia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Prematurely Ended) CZ (Prematurely Ended) PL (Completed) ES (Prematurely Ended) HR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012387-13 Sponsor Protocol Number: 102705 Start Date*: 2010-03-01
    Sponsor Name:McMaster University
    Full Title: PROTECT - Prophylaxis of ThromboEmbolism in Critical Care Trial
    Medical condition: Critically ill patients who require admission to the intensive care unit and need pharmacologic thromboprophylaxis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001954-40 Sponsor Protocol Number: SPh/01/2014 Start Date*: 2014-10-02
    Sponsor Name:SciencePharma spółka z ograniczoną odpowiedzialnością sp. k.
    Full Title: A randomized, multicenter, parallel, open-label study comparing the safety of the test investigational medicinal product (IMP) Enoxaparin Sodium 40 with the reference IMP Clexane for the prevention...
    Medical condition: Prevention of venous thromboembolism (VTE) in patients undergoing high VTE-risk knee surgery
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004865 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002190-10 Sponsor Protocol Number: UCDCRC/20/03 Start Date*: 2021-02-05
    Sponsor Name:University College Dublin
    Full Title: Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG)
    Medical condition: Coagulopathy of COVID-19 appears to afflict approximately 20% of patients with severe COVID-19 and is associated with need for critical care and death. COVID-19 coagulopathy is characterized by ele...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000284-21 Sponsor Protocol Number: 524E-CVD-9101-004 Start Date*: 2007-11-08
    Sponsor Name:York Hospitals NHS Foundation Trust [...]
    1. York Hospitals NHS Foundation Trust
    2. University of York
    Full Title: A multicentre, multinational randomised control trial of prophylactic low molecular weight heparin(LMWH) in high risk pregnant thrombophilic women
    Medical condition: Thrombophilia in pregnancy. This is a multi-centre, multi-national randomised controlled trial of Low Molecular Weight Heparin to prevent pregnancy complications in high-risk pregnant thrombophi...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10005329 - Blood and lymphatic system disorders 10057396 Thrombophilia LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004368-23 Sponsor Protocol Number: 20121005 Start Date*: 2012-11-02
    Sponsor Name:Odense University Hospital
    Full Title: Feasible strategy for preventing blood clots in critically ill patients with acute kidney Injury
    Medical condition: venous thromboembolism
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001341-14 Sponsor Protocol Number: BAY 59-7939 / 11527 Start Date*: 2004-11-04
    Sponsor Name:Bayer HealthCare AG
    Full Title: Controlled, Double-Blind, Randomized, Dose-ranging Study of once-daily regimen of BAY59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement-ODIXaHIP-OD Study
    Medical condition: Deep Venous Thrombosis prophylaxis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10012108
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) AT (Completed) ES (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005763-31 Sponsor Protocol Number: V1.610AUG2020 Start Date*: 2021-03-15
    Sponsor Name:Icahn School of Medicine at Mount Sinai
    Full Title: FREEDOM COVID Anticoagulation Strategy Randomized Trial
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 10:36:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA